INM on Nasdaq

InMed Pharmaceuticals Inc.

All dollar amounts stated herein are in U.S. dollars unless specified otherwise.5 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

-$12.6MNet income, fiscal 20263

Compare with SPRUCE BIOSCIENCES, INC., PROCYON CORP or Adlai Nortye Group Ltd., or pick any stock.

  • TickerINM on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersVancouver, Canada2
  • Incorporated inBritish Columbia, Canada4
  • Business addressC/O Norton Rose Fulbright Canada Llp, Suite 1800 - 510 West Georgia Street, Vancouver, V6B 0M34
  • Filer categoryNon-accelerated filer, Smaller reporting company4
  • Legal formCorporation2
  • LEI549300VA5DNHEJGHG3972
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered address#709 - 1445 West Georgia Street, V6C 3E8 Vancouver, Canada2
  • Registered withBC Registry Services, BC02349162

See how the biggest companies compare on our leaderboards

All dollar amounts stated herein are in U.S. dollars unless specified otherwise.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

34.5%Gross margin6
-165.1%Net margin3
7.5%Revenue growth, 20256
-60.8%Return on equity3

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue53¢$3.2M
  • Research and development47¢$2.8M

Out of $4.9M in revenue.63 The company lost money this year.

Financial statements

Revenue786$4.9M in 2025+160% since 2021
0$2.0M$4.0M$6.0M2021: $1.9M$1.9M20212022: $1.4M$1.4M2022−28%2023: $4.1M$4.1M2023+203%2024: $4.6M$4.6M2024+11%2025: $4.9M$4.9M2025+8%
Gross profit986$1.7M in 2025+214% since 2022
0$500.0K$1.0M$1.5M$2.0M2022: $543.5K$543.5K20222023: $1.4M$1.4M2023+158%2024: $1.1M$1.1M2024−22%2025: $1.7M$1.7M2025+55%
Operating income79-$7.9M in 2023−22% since 2021
-$20.0M-$15.0M-$10.0M-$5.0M02021: -$10.2M-$10.2M20212022: -$18.6M-$18.6M2022+82%2023: -$7.9M-$7.9M2023−57%
Net income1079863-$8.2M in 2025−9% since 2020
-$20.0M-$15.0M-$10.0M-$5.0M02020: -$8.9M-$8.9M20202021: -$10.2M-$10.2M2021+14%2022: -$18.6M-$18.6M2022+82%2023: -$7.9M-$7.9M2023−57%2024: -$7.7M-$7.7M2024−3%2025: -$8.2M-$8.2M2025+6%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2026-06-302025-06-30
Research and development$3.0M$2.8M
General and administrative$6.7M$5.4M
Amortization and depreciation$205.3K$210.4K
Loss on disposal of equipment$7.1K
Impairment of fixed assets$189.2K
Impairment of intangible assets$1.5M
Foreign exchange loss$58.0K$28.5K
Total operating expenses$11.6M$8.5M
Interest and other income$245.0K$155.9K
Finance expense-$10.7K-$371.5K
Loss from continuing operations before taxes-$11.4M-$8.7M
Net loss from continuing operations-$11.4M-$8.7M
Income (Loss) from discontinued operations-$1.2M$528.2K
Income (Loss) from discontinued operations-$1.2M$528.2K
Net Loss-$12.6M-$8.2M
Deemed dividends-$431.7K
Net loss attributable to common shareholders-$13.0M-$8.2M
Continuing operations, basic (in Dollars per share)-$3-$9
Continuing operations, diluted (in Dollars per share)-$3-$9
Discontinued operations, basic (in Dollars per share)-$0$1
Discontinued operations, diluted (in Dollars per share)-$0$1
Net loss per share attributable to Common Stockholders basic (in Dollars per share)-$3.12-$8.36
Net loss per share attributable to Common Stockholders diluted (in Dollars per share)-$3.12-$8.36
Basic (in Shares)4.2M shares975.9K shares
Diluted (in Shares)4.2M shares975.9K shares

Compare InMed Pharmaceuticals Inc. with another company

Leadership

Who has led InMed Pharmaceuticals Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Eric A. Adams2020–now

President

  1. Eric A. Adams2020–now

Chief financial officer

  1. Bruce Colwill2020–2022
  2. Brenda Edwards2022
  3. Jonathan Tegge2022–2023
  4. Netta Jagpal2024–now

Chief operating officer

  1. Michael Woudenberg2022–now
2025
Board members and other officers (14)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorJanet J. Grove named Jun 8, 2022 to Dec 6, 202232

Timeline

  1. Nov 12, 2020New chief executive Eric A. Adams becomes CEO13
  2. May 18, 1981Founded InMed Pharmaceuticals Inc. is founded2

Filings

396 filings to the SEC since October 2021: 8 annual reports, 15 quarterly reports, 132 major events, 121 insider forms, 15 large holders, 3 private raises, 102 other. The latest 20:

  1. Oct 15, 20264 PRIMARY DOCUMENT EDGAR
  2. Oct 8, 20264 PRIMARY DOCUMENT EDGAR
  3. Oct 7, 2026SCHEDULE 13G/A EDGAR
  4. Oct 5, 20264 PRIMARY DOCUMENT EDGAR
  5. Oct 1, 2026EFFECT EDGAR
  6. Oct 1, 2026424B3 EDGAR
  7. Sep 29, 2026S-4/A EDGAR
  8. Sep 18, 20268-K CURRENT REPORT EDGAR
  9. Sep 16, 20264 PRIMARY DOCUMENT EDGAR
  10. Sep 9, 2026425 EDGAR
  11. Sep 9, 202610-K ANNUAL REPORT EDGAR
  12. Sep 9, 2026S-4/A EDGAR
  13. Aug 14, 2026SCHEDULE 13G EDGAR
  14. Jul 22, 2026425 EDGAR
  15. Jul 22, 2026425 CURRENT REPORT EDGAR
  16. Jul 22, 20268-K CURRENT REPORT EDGAR
  17. Jul 20, 2026425 EDGAR
  18. Jul 17, 20264 PRIMARY DOCUMENT EDGAR
  19. Jul 16, 20264 EDGAR
  20. Jul 10, 2026425 CURRENT REPORT EDGAR

The 396 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

29 open-market trades by officers, directors and large owners since October 2021: 28 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 16, 2026Schneeberger Daniel10% ownerBuy8,340$1.29$10.8KForm 4
Sep 15, 2026Schneeberger Daniel10% ownerBuy54,256$1.30$70.5KForm 4
Sep 14, 2026Schneeberger Daniel10% ownerBuy28,505$1.29$36.8KForm 4
Jul 16, 2026Vivo Opportunity Cayman Fund, L.P.10% ownerBuy21$1.55$33Form 4
Jul 15, 2026ADAR1 Capital Management, LLC10% ownerBuy1,000$1.56$1.6KForm 4
Jul 15, 2026Vivo Opportunity Cayman Fund, L.P.10% ownerBuy15,150$1.55$23.5KForm 4
Jul 14, 2026Vivo Opportunity Cayman Fund, L.P.10% ownerBuy5,375$1.55$8.3KForm 4
Jul 2, 2026Vivo Opportunity, LLC10% ownerBuy1,607$1.55$2.5KForm 4
Jul 1, 2026Vivo Opportunity, LLC10% ownerBuy4,344$1.55$6.7KForm 4
Jun 30, 2026Vivo Opportunity, LLC10% ownerBuy600$1.54$924Form 4
Jun 8, 2026Vivo Opportunity, LLC10% ownerBuy32,500$1.52$49.4KForm 4
Jun 5, 2026Vivo Opportunity, LLC10% ownerBuy55,011$1.57$86.4KForm 4
Jun 4, 2026Vivo Opportunity, LLC10% ownerBuy6,743$1.57$10.6KForm 4
Jun 3, 2026Vivo Opportunity, LLC10% ownerBuy7,783$1.55$12.1KForm 4
Jun 2, 2026Vivo Opportunity, LLC10% ownerBuy22,848$1.52$34.7KForm 4
Jun 1, 2026Vivo Opportunity, LLC10% ownerBuy16,336$1.55$25.3KForm 4
May 29, 2026Vivo Opportunity, LLC10% ownerBuy17,796$1.57$27.9KForm 4
May 21, 2026Vivo Opportunity, LLC10% ownerBuy34,000$1.69$57.5KForm 4
May 20, 2026Vivo Opportunity, LLC10% ownerBuy56,210$1.56$87.7KForm 4
May 19, 2026Schneeberger Daniel10% ownerBuy468,551$1.54$721.7KForm 4

All 29 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Nov 21, 2022Raised $6 million in a private offering of equity Form D: 2 investors so far Form D
  2. Jun 6, 2022Raised $5 million in a private offering of equity Form D: 1 investor so far Form D
  3. Oct 13, 2021Raised $4.3 million in a private offering of equity Form D: 54 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
ADAR1 Capital Management, LLC800,000$1.2M0.1%New
Vivo Capital, LLC798,377$1.2M0.1%New
Squadron Capital Management LLC325,000$503.8K0.2%New
Ikarian Capital, LLC245,025$379.8K0.1%New
Ursa Fund Management, LLC125,800$195.0K0.0%New
Montanova Capital, LLC100,000$155.0K0.0%New
Boothbay Fund Management, LLC74,244$115.1K0.0%New
Sabby Management, LLC44,970$69.7K0.6%−175,290
Jane Street Group, LLC43,078$66.8K0.0%New
Venrock Adviser, LLC32,685$50.7K0.0%New
Citadel Advisors LLC26,084$40.4K0.0%−20,889
Seven Grand Managers, LLC25,000$38.8K0.0%New
Scientech Research LLC15,461$24.0K0.0%New
Crestwood Advisors Group, LLC14,900$23.1K0.0%New
Two Sigma Securities, LLC10,945$17.0K0.0%−7,773
Stratos Wealth Partners, LTD.10,760$16.7K0.0%New
Private Wealth Management Group, LLC5,000$7.8K0.0%No change
Banque Cantonale Vaudoise6$1.0K0.0%No change
SBI Securities Co., Ltd.300$4650.0%No change
Federation des caisses Desjardins du Quebec2$40.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40